JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M000287200 on April 3, 2000

J. Biol. Chem., Vol. 275, Issue 22, 16690-16696, June 2, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/22/16690    most recent
M000287200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kanoh, Y.
Right arrow Articles by Farese, R. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kanoh, Y.
Right arrow Articles by Farese, R. V.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Thiazolidinedione Treatment Enhances Insulin Effects on Protein Kinase C-zeta /lambda Activation and Glucose Transport in Adipocytes of Nondiabetic and Goto-Kakizaki Type II Diabetic Rats*

Yoshinori Kanoh, Gautam Bandyopadhyay, Mini P. Sajan, Mary L. Standaert, and Robert V. FareseDagger

From the J. A. Haley Veterans Hospital Research Service and Department of Internal Medicine, University of South Florida College of Medicine Tampa, FL 33612

Received for publication, January 13, 2000, and in revised form, March 3, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We evaluated effects of the thiazolidinedione, rosiglitazone, on insulin-induced activation of protein kinase C (PKC)-zeta /lambda and glucose transport in adipocytes of Goto-Kakizaki (GK)-diabetic and nondiabetic rats. Insulin effects on PKC-zeta /lambda and 2-deoxyglucose uptake were diminished by approximately 50% in GK adipocytes, as compared with control adipocytes. This defect in insulin-induced PKC-zeta /lambda activation was associated with diminished activation of IRS-1-dependent phosphatidylinositol (PI) 3-kinase, and was accompanied by diminished phosphorylation of threonine 410 in the activation loop of PKC-zeta ; in contrast, protein kinase B (PKB) activation and phosphorylation were not significantly altered. Rosiglitazone completely reversed defects in insulin-stimulated 2-deoxyglucose uptake, PKCzeta /lambda enzyme activity and PKC-zeta threonine 410 phosphorylation, but had no effect on PI 3-kinase activation or PKB activation/phosphorylation in GK adipocytes. Similarly, in adipocytes of nondiabetic rats, rosiglitazone provoked increases in insulin-stimulated 2-deoxyglucose uptake, PKC-zeta /lambda enzyme activity and phosphorylation of both threonine 410 activation loop and threonine 560 autophosphorylation sites in PKC-zeta , but had no effect on PI 3-kinase activation or PKB activation/phosphorylation. Our findings suggest that (a) decreased effects of insulin on glucose transport in adipocytes of GK-diabetic rats are due at least in part to diminished phosphorylation/activation of PKC-zeta /lambda , and (b) thiazolidinediones enhance glucose transport responses to insulin in adipocytes of both diabetic and nondiabetic rats through increases in phosphorylation/activation of PKC-zeta /lambda .

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Thiazolidinediones (TZDs),1 as activators of peroxisome proliferator-activated receptor-gamma , serve as clinically important insulin-sensitizing agents and improve overall glucose homeostasis in type II diabetes mellitus (1). Improvement in glucose homeostasis following TZD treatment is primarily due to enhanced effects of insulin on glucose transport and subsequent storage in skeletal muscle (2), and, to a lesser extent, in adipose tissue. Despite the widespread use and effectiveness of TZDs in treating type II diabetes mellitus, the underlying mechanism(s) of action of TZD remains uncertain. Whereas TZDs may provoke increases in the levels of GLUT4 (3) or GLUT1 (4) glucose transporters, TZD treatment can also enhance insulin-stimulated GLUT4 translocation to the plasma membrane or glucose transport in the absence of changes in the level of glucose transporters (5, 6). With respect to signaling factors that insulin uses to stimulate GLUT4 translocation and subsequent glucose transport, phosphatidylinositol (PI) 3-kinase is now generally recognized to be a key factor (7). In this regard, although TZDs have been reported to increase PI 3-kinase activity or reverse defects in insulin-induced activation of PI 3-kinase in certain situations (e.g. see Ref. 8), alterations in PI 3-kinase have not been observed (9) or reported in many studies.

Presently, to gain further insight into the mechanism of action of TZDs, we examined the potential role of two protein kinases that are postulated to function distally to PI 3-kinase during insulin regulation of GLUT4 translocation and glucose transport, namely protein kinase C-zeta /lambda (PKC-zeta /lambda ) (10-14) and protein kinase B (PKB or Akt) (15-18). For this purpose, we examined the effects of TZD treatment on insulin-induced activation of these kinases in adipocytes of both nondiabetic rats and non-obese type II diabetic Goto-Kakizaki (GK) rats. In the GK-diabetic rat (originally derived by repeated in-breeding of glucose-intolerant Wistar rats), plasma insulin levels are initially low (19), but, as plasma glucose levels rise, plasma insulin levels increase (20, 21), presumably compensatorily, and may be mildly elevated (in an absolute sense, but still relatively low for the degree of hyperglycemia) for a limited time (22). In conjunction with hyperglycemia and possibly modest hyperinsulinemia, an apparently secondary form of insulin resistance occurs, as evidenced by defects in (a) both hepatic glucose output and peripheral glucose disposal in muscle (20, 21) and adipose (20) tissues during euglycemic-hyperinsulinemic clamp studies, and (b) GLUT4 translocation and/or glucose transport in isolated adipocytes (23) and skeletal muscle preparations (24, 25). In association with decreases in glucose transport, impaired activation of IRS-1-dependent PI 3-kinase by insulin has also been observed in the slow twitch soleus muscle, but not in the fast twitch extensor digitorum longis muscle, of the GK rat (25). The activation of PKB by insulin has been reported to be impaired in both of these muscles in GK rats, but the reversal of these defects in PKB activation and glucose transport by blood sugar normalization (by prolonged treatment with phlorizin) did not appear to be explained by alterations in PI 3-kinase activation (25). As reported here, we found that, in conjunction with defects in insulin-stimulated glucose transport and PI 3-kinase activation, there are defects in the phosphorylation and enzymatic activation of PKC-zeta /lambda in adipocytes isolated from GK rats. Of further interest, in vivo treatment with the TZD rosiglitazone reversed the defects in insulin-stimulated glucose transport and PKC-zeta /lambda phosphorylation/activation in vitro, but had no apparent effect on PI 3-kinase activation or PKB activation/phosphorylation in adipocytes isolated from GK rats. Rosiglitazone treatment in vivo also provoked increases in insulin-induced increases in phosphorylation and activation of PKC-zeta /lambda and glucose transport in adipocytes isolated from nondiabetic, as well as GK-diabetic, rats, but, again, without altering PI 3-kinase activation or PKB activation/phosphorylation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Experimental Rats and Treatment with Rosiglitazone in Vivo-- A colony of GK rats, originally obtained from Drs. S. Suzuki and T. Toyota (Tohoku University, Sendai, Japan), has been maintained in our vivarium for the past 7 years. All offspring in this colony have been consistently hyperglycemic, and peripheral insulin resistance in these offspring has been documented in clamp studies (21). As controls for GK-diabetic rats, we used nondiabetic Wistar rats, which were purchased from Harlan Industries. We also used 10-14-week-old male nondiabetic Harlan Sprague-Dawley rats. All rats were fed the same diet and kept for at least 2 weeks prior to experimental use in the same environment in our vivarium, which is temperature-controlled and maintains daily 12-h light/dark cycles. Male Wistar and GK rats were used at approximately 10-14 weeks of age (body weight, 250-300 g), at which time serum insulin levels in GK rats may be mildly increased (22). Where indicated, rosiglitazone (1 mg/day) (kindly supplied by SmithKline Beecham) was given by oral gavage for 6-14 days; this dose was selected as it is proportional to that found to be fully effective for restoring glucose transport responses over a comparable time course in a previous study of ob/ob mouse adipocytes (26) and comparable to that found to be effective for rapidly altering peroxisome proliferator-activated receptor-gamma -sensitive gene expression in high fat-fed rats (27).

Preparation and Incubations of Rat Adipocytes-- As described (12, 28), rat adipocytes were prepared by collagenase digestion of epididymal fat pads and incubated for indicated times in glucose-free Krebs-Ringer phosphate (KRP) medium containing 1% bovine serum albumin and indicated concentrations of insulin. After incubation, cells were used for studies of glucose transport (see below), or chilled and sonicated in the following buffers for assays of immunoprecipitable PKC-zeta /lambda , PI 3-kinase, or PKB. For studies of PKC-zeta /lambda activation, as described (12, 28), buffer contained 250 mM sucrose, 20 mM Tris/HCl (pH 7.5), 1.2 mM EGTA, 20 mM beta -mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml aprotinin, 20 µg/ml leupeptin, 3 mM Na3VO4, 3 mM NaF, 3 mM Na4P2O7, and 1 µM LR-microcystin. For studies of PI 3-kinase activation, as described (12), buffer contained 255 mM sucrose, 20 mM Tris/HCl (pH 7.4), 5 mM EDTA, 5 mM EGTA, 1 mM Na3VO4, 1 mM NaF, 1 mM Na4P2O7, 1 mM PMSF, 10 µg/ml aprotinin, 20 µg/ml leupeptin, and 1 µM LR-microcystin. For studies of PKB activation, buffer contained 50 mM Tris/HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 0.1% beta -mercaptoethanol, 50 mM NaF, 5 mM Na4P2O7, 10 mM beta -glycerophosphate, 1 mM PMSF, 10 µg/ml aprotinin, 20 µg/ml leupeptin, and 1 µM LR-microcystin. Homogenates were centrifuged for 10 min at 700 × g to remove nuclei, cellular debris, and floating fat. Supernatants were then supplemented with (a) 0.15 M NaCl, 1% Triton X-100, and 0.5% Nonidet and used for immunoprecipitation of PKC-zeta /lambda or PI 3-kinase, or with (b) 1% Triton X-100 for immunoprecipitation of PKB, as described below.

Studies of Glucose Transport-- As described (10, 12, 28), adipocytes were equilibrated in glucose-free KRP medium and treated for 30 min with or without indicated concentrations of insulin, following which 2-deoxyglucose (0.2 µCi; 50 µM; NEN Life Science Products) uptake was measured over a 1-min period.

Studies of PKC-zeta /lambda Activation and Autophosphorylation-- As described previously (12, 28), cell lysates were immunoprecipitated overnight at 0-4 °C with a polyclonal antiserum (Santa Cruz Biotechnologies, Santa Cruz, CA) that recognizes the C termini of both PKC-zeta and PKC-lambda (as shown below, rat tissues primarily contain PKC-zeta , whereas mouse tissues primarily contain PKC-lambda ). Precipitates were collected on protein AG-Sepharose beads, washed, and incubated for 8 min at 30 °C in 100 µl of buffer containing 50 mM Tris/HCl (pH, 7.5), 5 mM MgCl2, 100 µM Na3VO4, 100 µM Na4P2O7, 1 mM NaF, 100 µM PMSF, 50 µM ATP, 3-5 µCi of [gamma -32P]ATP (NEN Life Science Products), 4 µg of phosphatidylserine, and 40 µM serine 159 analogue of the PKC-epsilon pseudosubstrate (amino acids, 153-164) (Quality Controlled Biochemicals), as described previously (12, 28). In autophosphorylation assays, the exogenous substrate was omitted from the PKC-zeta /lambda assay, and, after incubation, aliquots of the assay mixtures were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, and examined for 32P radioactivity in 75 kDa PKC-zeta /lambda with a Bio-Rad PhosphorImager as described (12, 28).

Studies of PKB Activation-- As described (28), PKB activation was assessed by (a) measurement of immunoprecipitable PKB using a kit obtained from Upstate Biotechnologies, Inc. (UBI), or (b) by immunoblotting for phosphorylation of serine 473, which is dependent upon the actions of PI 3-kinase and 3-phosphoinositide-dependent protein kinases-1 and 2 (PDK-1 and 2).

Studies of PI 3-Kinase Activation-- Cell lysates were immunoprecipitated overnight at 0-4 °C with anti-IRS-1 antibodies (kindly supplied by Dr. Alan Saltiel) or anti-phosphotyrosine antibodies (obtained from Santa Cruz Biotechnologies, Santa Cruz, CA) and assayed for PI 3-kinase enzyme activity as described (12).

Western Analyses-- As described previously (12, 13, 28), cell lysates and immunoprecipitates were boiled and stored in Laemmli buffer, subjected to SDS-PAGE, transferred to nitrocellulose membranes, and blotted with the following: (a) rabbit polyclonal anti-PKC-zeta /lambda antiserum that recognizes the C termini of both PKC-zeta and PKC-lambda (Santa Cruz Biotechnologies); (b) sheep polyclonal anti-PKB antiserum (UBI); (c) rabbit polyclonal anti-p85alpha subunit/PI 3-kinase antiserum (UBI); (d) sheep polyclonal anti-PDK-1 antiserum (UBI); (e) rabbit polyclonal anti-phosphoserine 473-PKB antiserum (New England Biolabs); (f) rabbit polyclonal anti-GLUT1 antiserum (kindly supplied by Dr. Ian Simpson); (g) rabbit polyclonal anti-GLUT4 antiserum (Biogenesis); (h) rabbit polyclonal anti-phosphothreonine 410-PKC-zeta antiserum (kindly supplied by Dr Alex Toker; see Ref. 28); (i) goat polyclonal anti-PKC-zeta antiserum that recognizes a specific N-terminal sequence in PKC-zeta ; and (j) mouse monoclonal anti-PKC-lambda antibodies that recognize a specific internal sequence in PKC-lambda . Blot bands were quantitated by measurement of chemiluminescence using a Bio-Rad Molecular Analyst Chemiluminescence/PhosphorImager System.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Studies in Wistar Nondiabetic and GK-diabetic Rat Adipocytes

PKC-zeta /lambda Activation and Phosphorylation-- Similar to findings in previous studies of adipocytes of Harlan Sprague-Dawley rats (12, 28), insulin provoked nearly a 2-fold increase (p < 0.001; see Fig. 1 legend for statistical methods) in immunoprecipitable PKC-zeta /lambda enzyme activity in adipocytes isolated from Wistar nondiabetic rats (Fig. 1). Interestingly, the effect of insulin on PKC-zeta /lambda activity was approximately 50% lower in adipocytes of GK-diabetic rats (p < 0.001, comparison to insulin effect on PKC-zeta /lambda activity in adipocytes of Wistar nondiabetic rats), and, moreover, this defect in PKC-zeta /lambda activation was more than completely reversed by 10-14 days of rosiglitazone treatment (p < 0.001). Of further note, rosiglitazone treatment provoked 20-30% increases (also see Harlan Sprague-Dawley studies below) in basal (not significant) and insulin-stimulated (p < 0.01) PKC-zeta /lambda enzyme activity in adipocytes of Wistar nondiabetic, as well as GK-diabetic rats (Fig. 1).


View larger version (32K):
[in this window]
[in a new window]
  		Fig. 1.   Effects of insulin and rosiglitazone treatment on immunoprecipitable PKC-zeta /lambda enzyme activity in adipocytes isolated from Wistar nondiabetic (W) and GK-diabetic (G) rats. Rats were treated first with rosiglitazone in vivo for 10-14 days, and adipocytes were then prepared and incubated in glucose-free KRP medium with or without 10 nM insulin for 10 min, after which immunoprecipitable PKC-zeta /lambda enzyme activity was measured as described under "Experimental Procedures." Bar graphs and brackets depict mean ± S.E. of (n) determinations. p values given in the text were determined by 2 × 2 × 2 factorial analysis of variance.

Alterations in PKC-zeta /lambda enzyme activity were accompanied by similar alterations in the phosphorylation of threonine 410 in the activation loop of PKC-zeta . As seen in Fig. 2, in the absence of rosiglitazone treatment, insulin effects on threonine 410 phosphorylation were greater in adipocytes isolated from Wistar nondiabetic, as compared with GK-diabetic, rats; moreover, rosiglitazone treatment provoked increases in basal, as well as insulin-stimulated, threonine 410 phosphorylation in Wistar nondiabetic and, even more so, in GK-diabetic adipocytes.


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 2.   Effects of insulin (INS) and rosiglitazone (RSGZ) treatment on phosphorylation of threonine 410 in the activation loop of PKC-zeta in adipocytes isolated from Wistar nondiabetic and GK-diabetic rats. Rats were treated with rosiglitazone, and adipocytes were prepared and treated with or without insulin as in Fig. 1, after which cellular lysates (1 mg of protein) were subjected to immunoprecipitation with anti-PKC-zeta /lambda antibodies, resolution on SDS-PAGE, and immunoblotting with antibodies that recognize the peptide sequence surrounding phosphothreonine 410 in PKC-zeta as described under "Experimental Procedures." Shown here are representative blots and bar graphs/brackets that depict mean ± S.E. of three determinations, plotted relative to the Wistar control (also see Figs. 8 and 9 for more determinations in Harlan Sprague-Dawley rats).

PI 3-Kinase Activation-- The decrease in insulin-induced activation of PKC-zeta /lambda in GK adipocytes was accompanied by decreased activation of IRS-1-dependent PI 3-kinase (Fig. 3). However, in contrast to PKC-zeta /lambda , rosiglitazone did not alter basal or insulin-stimulated PI 3-kinase activity (Fig. 3).


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 3.   Effects of insulin and rosiglitazone (RSGZ) on IRS-1-dependent PI 3-kinase activity in adipocytes isolated from Wistar nondiabetic and GK-diabetic rats. Rats were treated with rosiglitazone in vivo and incubated in vitro for 10 min with or without 10 nM insulin as in Fig. 1. After incubation, PI 3-kinase activity was measured as described under "Experimental Procedures." Shown here is a representative autoradiogram and bar graphs/brackets depicting mean ± S.E. of three determinations, plotted relative to the Wistar control.

PKB Activation-- In association with defects in insulin-induced increases in PI 3-kinase activity and phosphorylation and activation of PKC-zeta /lambda , insulin-induced activation of PKB, as assessed by measurement of PKB enzyme activity, appeared to be diminished mildly by approximately 20% (Fig. 4), although increases in immunoreactive phosphoserine 473-PKB (Fig. 5) did not appear to be altered in adipocytes isolated from GK-diabetic rats. More importantly, rosiglitazone treatment was without effect on either PKB enzyme activity or phosphorylation in adipocytes isolated from either Wistar nondiabetic or GK-diabetic rats (Figs. 4 and 5).


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 4.   Effects of insulin and rosiglitazone (RSGZ) on PKB enzyme activity in adipocytes isolated from Wistar nondiabetic and GK-diabetic rats. Experiments were conducted as in Figs. 1-3, except that, after incubation, immunoprecipitable PKB enzyme activity was measured as described under "Experimental Procedures." Shown here are mean ± S.E. of three determinations.


View larger version (46K):
[in this window]
[in a new window]
  		Fig. 5.   Effects of insulin (INS) and rosiglitazone (RSGZ) treatment on levels of immunoreactive PI 3-kinase (PI3K) p85alpha subunit, PDK-1 (PDK), PKB, phosphoserine 473-PKB (pPKB), PKC-zeta /lambda , GLUT1, and GLUT4 in adipocytes isolated from Wistar nondiabetic and GK-diabetic rats. Cell lysates from adipocytes used in Figs. 1-3 were analyzed as described under "Experimental Procedures." Shown here are blots that are representative of at least four determinations. As is apparent, aside from phosphorylation-dependent shifts in PKB and PKC-zeta /lambda , and, aside from increases in phospho-PKB following insulin treatment, there were no significant alterations in depicted proteins that could be attributed to either the GK-diabetic state or to insulin or rosiglitazone treatment (also see Figs. 8 and 9).

2-Deoxyglucose Uptake Studies-- In conjunction with decreased activation of PKC-zeta /lambda , maximal effects of insulin on 2-deoxyglucose uptake were diminished by approximately 50% in adipocytes isolated from GK-diabetic rats, as compared with uptake observed in adipocytes isolated from Wistar nondiabetic rats; the Km, however, was not altered (Fig. 6). Further, in association with the enhancement of insulin-induced PKC-zeta /lambda activation in adipocytes obtained from both Wistar nondiabetic and GK-diabetic rats, rosiglitazone treatment enhanced both the maximal and half-maximal effects of insulin on 2-deoxyglucose uptake in adipocytes of both Wistar nondiabetic and GK-diabetic rats, and the presently observed defect in glucose transport in GK-diabetic adipocytes was no longer apparent (Fig. 6).


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 6.   Effects of insulin and rosiglitazone (RSGZ) treatment on [3H]2-deoxyglucose uptake in adipocytes isolated from Wistar nondiabetic, GK-diabetic, and Harlan Sprague-Dawley nondiabetic rats. As described under "Experimental Procedures," rats were treated in vivo with rosiglitazone for 10-14 days (Wistar and GK) or for 6-7 days (Harlan Sprague-Dawley). Adipocytes were isolated from treated and untreated rats, equilibrated in glucose-free KRP medium, and treated for 30 min with or without indicated concentrations of insulin, following which, uptake of 3H-labeled 2-deoxyglucose was measured over a 1-min interval as described under "Experimental Procedures." Shown here are mean ± S.E. of (n) fully separate experiments, each conducted in triplicate or quadruplicate.

The levels of immunoreactive PI 3-kinase/p85alpha subunit, PDK-1, PKB, pPKB (phosphoserine 473-PKB), combined PKC-zeta /lambda , GLUT1, and GLUT4 were comparable, in adipocytes isolated from Wistar nondiabetic and GK-diabetic rats, and were not altered significantly by rosiglitazone treatment (Fig. 5).

It may be noted that the recovery of (a) combined immunoreactive PKC-zeta /lambda (assessed with an antiserum that recognizes the C termini of both PKC-zeta and PKC-lambda ); (b) immunoreactive PKC-lambda (assessed with antibodies that specifically recognize an internal sequence of PKC-lambda ); and (c) immunoreactive PKC-zeta (assessed with an antiserum that specifically recognizes a sequence in the N terminus of PKC-zeta ) in PKC-zeta /lambda immunoprecipitates was comparable in all experimental groups and was not altered by diabetes, rosiglitazone treatment, or insulin treatment (Fig. 7). Additionally, note that it was necessary to use relatively large amounts of lysates (1 mg) for immunoprecipitation to detect the seemingly strong signals for PKC-lambda shown in Fig. 7. As also shown in Fig. 7, in comparing lesser amounts (75 µg) of whole cell lysates prepared from rat and mouse adipocytes, it is evident that, despite having comparable levels of total immunoreactive atypical PKC-zeta plus PKC-lambda (PKC-zeta /lambda blot), rat adipocytes are relatively rich in PKC-zeta , and mouse adipocytes are relatively rich in PKC-lambda .


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 7.   Recovery of combined PKC-zeta plus PKC-lambda , PKC-zeta , and PKC-lambda in PKC-zeta /lambda immunoprecipitates prepared from adipocytes isolated from control and insulin-treated Wistar nondiabetic and GK-diabetic rats. Rats were treated in vivo with or without rosiglitazone and adipocytes were prepared and treated in vitro with or without insulin, as in Figs. 1-3. After incubation, cell lysates (1 mg of protein) were immunoprecipitated with anti-C-terminal antiserum that recognizes both PKC-zeta and PKC-lambda , and precipitates were blotted with indicated antibodies (alpha ). Also shown here are immunoblots of cell lysates (75 µg of protein) prepared from rat and mouse adipocytes.

Studies in Harlan Sprague-Dawley Nondiabetic Adipocytes

The effects of rosiglitazone in nondiabetic adipocytes were explored further in Harlan Sprague-Dawley rats. As seen in Fig. 8, rosiglitazone treatment for 6-7 days provoked 45% and 65% increases in basal and insulin-stimulated PKC-zeta /lambda enzyme activity, and the increment in PKC-zeta /lambda enzyme activity owing to insulin treatment was increased by 87% (PKC-zeta /lambda activity in each of the four groups in Fig. 8 was significantly different, i.e. p < 0.05, from all other groups, as determined by one-way analysis of variance and the Sheffe post hoc test for multiple comparisons). (Note: the reason for greater effects of rosiglitazone in adipocytes of Harlan Sprague-Dawley rats, as compared with those of Wistar rats, is presently uncertain, but could be due to strain differences, shorter duration of rosiglitazone treatment, and/or the greater sample size in the Harlan Sprague-Dawley study.). In contrast to the enhancement of insulin-induced activation of PKC-zeta /lambda , the activation of phosphotyrosine-associated PI 3-kinase (Fig. 9) and the phosphorylation of serine 473 in PKB (Figs. 8 and 9) were not enhanced by 6-7-day rosiglitazone treatment.


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 8.   Effects of insulin and rosiglitazone (RSGZ) treatment on PKC-zeta /lambda enzyme activity, phosphorylation of threonine 410 in PKC-zeta , and phosphorylation of serine 473 in PKB in adipocytes prepared from nondiabetic Harlan Sprague-Dawley rats. As described under "Experimental Procedures," rats were treated in vivo with rosiglitazone for 6-7 days, and adipocytes were isolated from treated and untreated rats and incubated in glucose-free KRP medium for 10 min with or without 10 nM insulin, after which cellular lysates were examined for changes in PKC-zeta /lambda enzyme activity (panel A), and, by Western analysis, for threonine 410 phosphorylation (panel B) and PKB serine 473 phosphorylation (panel C). Bar graphs and brackets reflect mean ± S.E. of (n) determinations.


View larger version (43K):
[in this window]
[in a new window]
  		Fig. 9.   Effects of insulin and rosiglitazone (RSGZ) treatment on PI 3-kinase activity, phosphorylation of threonine 410 in PKC-zeta , and autophosphorylation of PKC-zeta (right) and levels of immunoreactive PI 3-kinase p85alpha subunit (PI3K), PDK-1 (PDK), PKB, phosphoserine 473-PKB (pPKB), PKC-zeta /lambda , GLUT1, and GLUT4 (left) in adipocytes prepared from nondiabetic Harlan Sprague-Dawley rats. As described under "Experimental Procedures," rats were treated in vivo with rosiglitazone for 6-7 days, and adipocytes were isolated from treated and untreated rats and incubated in glucose-free KRP medium for 10 min with or without 10 nM insulin, after which cell lysates were examined for changes in immunoreactive PI 3-kinase p85alpha subunit, PDK-1, PKB, pPKB, PKC-zeta /lambda , and GLUT1 and GLUT4 glucose transporters, as shown in the left panel. Shown on the right, (a) the PI3P autoradiogram reflects radioactivity recovered in PI-3-PO4 following assay of phosphotyrosine-associated PI 3-kinase, lipid extraction, and thin layer chromatography; (b) the alpha -p410 immunoblot reflects immunoreactive phosphothreonine 410 in PKC-zeta following resolution on SDS-PAGE; and (c) the 32P-zeta /lambda autoradiogram reflects autophosphorylation of 32P-labeled PKC-zeta /lambda following assay and resolution on SDS-PAGE. Autoradiograms and immunoblots are representative of at least four determinations. See also Fig. 8 for mean values and standard errors for PKC-zeta /lambda enzyme activity, threonine 410 phosphorylation in PKC-zeta , and phosphoserine 473 phosphorylation in PKB as observed in multiple samples.

In association with rosiglitazone-induced increases in PKC-zeta /lambda enzyme activity in adipocytes isolated from Harlan Sprague-Dawley nondiabetic rats, rosiglitazone treatment provoked increases in basal and insulin-stimulated levels of (a) PDK-1-dependent phosphorylation of threonine 410 in the activation loop of PKC-zeta (Figs. 8 and 9) and (b) subsequent autophosphorylation of PKC-zeta , presumably involving threonine 560 (Fig. 9). Additionally, as in adipocytes of Wistar nondiabetic rats, rosiglitazone treatment provoked increases in insulin-stimulated glucose transport in adipocytes isolated from Harlan Sprague-Dawley nondiabetic rats (Fig. 6).

As in Wistar-nondiabetic adipocytes, rosiglitazone treatment had no effects on the levels of immunoreactive PI 3-kinase/p85alpha subunit, PKD-1, PKB, PKC-zeta /lambda , GLUT1, and GLUT4 in adipocytes of Harlan Sprague-Dawley nondiabetic rats (Fig. 9).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

It was of considerable interest to find that the activation of PKC-zeta /lambda by insulin was impaired in adipocytes of GK-diabetic rats. This defect could not be explained by reduced levels of PKC-zeta , PKC-lambda , PDK-1, or the p85alpha subunit of PI 3-kinase. On the other hand, this defect in insulin-stimulated PKC-zeta /lambda enzyme activation in GK adipocytes was associated with decreases in IRS-1-dependent PI 3-kinase activation and PDK-1-dependent phosphorylation of threonine 410 in the activation loop of PKC-zeta . It is therefore reasonable to suggest that the GK-diabetic state led to a diminution in the activity or action of factors that are upstream of PKC-zeta , i.e. PI 3-kinase and PDK-1, which, in turn, diminished PKC-zeta /lambda phosphorylation and activity; however, in this scenario, since insulin-stimulated activation of PKB was inhibited to a lesser degree than PKC-zeta /lambda , it would be necessary to postulate that, as compared with PKC-zeta /lambda , PKB is more effectively activated at lower levels of PI 3-kinase activation, or there are separate pools of upstream signaling factors, including PI 3-kinase and PDK-1, that regulate PKC-zeta /lambda and PKB. As another alternative, it is possible that the diabetic state, as existing in GK rats, may be attended by an increase in the activity of a factor that negatively modulates PKC-zeta /lambda , e.g. by dephosphorylation of the activation loop and/or autophosphorylation sites, or by inhibition of the catalytic or substrate-binding sites of both PKC-zeta /lambda , irrespective of, or in addition to, PI 3-kinase and PDK-1 activation. In this regard, it is of interest that (a) okadaic acid, which inhibits protein phosphatase-2A (PP2A), activates PKC-zeta (29), and (b) increases in basal cytosolic PP2A activity, as well as diminished inhibition of PP2A activity in response to acute treatment with insulin, have been observed in adipocytes of GK-diabetic rats (23). Further studies are needed to more fully define the mechanism of inhibition of insulin-stimulated PKC-zeta /lambda activation in adipocytes of GK-diabetic rats.

It was also of considerable interest that rosiglitazone not only corrected the defects in insulin-stimulated PKC-zeta threonine 410 phosphorylation and enzymatic activity of PKC-zeta /lambda in adipocytes of GK-diabetic rats, but also increased the phosphorylation of the threonine 410 loop and threonine 560 autophosphorylation sites of PKC-zeta , as well as the enzymatic activity of PKC-zeta /lambda , in adipocytes of nondiabetic rats. Moreover, these increases in PKC-zeta /lambda phosphorylation and activation were not associated with alterations in IRS-1-dependent PI 3-kinase activity or activation by insulin in diabetic and nondiabetic adipocytes. These findings suggested that (a) rosiglitazone provoked an alteration in a factor that either enhanced the phosphorylation, or diminished the dephosphorylation, of loop and autophosphorylation sites in PKC-zeta /lambda , and (b) stimulatory effects of rosiglitazone on PKC-zeta /lambda were not explicable simply on the basis of reversing the action of a uniquely diabetes-associated inhibitory factor.

The mechanism whereby rosiglitazone enhanced phosphorylation and subsequent activation of PKC-zeta /lambda is uncertain. Since phosphorylation of threonine 410 in the activation loop of PKC-zeta was enhanced by rosiglitazone, as alluded to above, it is possible that the activity or action of PDK-1, which, along with PIP3, regulates this loop phosphorylation (12, 28, 30, 31), may have been increased by rosiglitazone treatment. In evaluating this possibility, it may be noted that increases in threonine 410 loop phosphorylation in the basal and insulin-stimulated state were not always paralleled by strictly proportional increases in PKC-zeta /lambda enzyme activity, or, for that matter, in glucose transport. This lack of strict proportionality may reflect the fact that, in addition to increases in PDK-1 action, the full activation of PKC-zeta /lambda requires (a) PIP3- dependent enhancement of autophosphorylation of threonine 560 (28), as presently observed with rosiglitazone treatment, and (b) PIP3-dependent conformational changes that are phosphorylation-independent, most likely involving the relief of pseudosubstrate autoinhibition2; moreover, increases in specific insulin-sensitive pools of membrane-associated PIP3 and PIP3-dependent kinases, such as PKC-zeta /lambda and PKB, are probably of major importance in the activation of glucose transport. Additionally, in evaluating the possibility that rosiglitazone may have acted via PDK-1, it is important to note that we did not detect significant effects of rosiglitazone on PI 3-kinase activation, or on phosphorylation or activation of PKB, which, like PKC-zeta /lambda , is regulated by PDK-1 (32, 33). It therefore seems unlikely that rosiglitazone provoked a generalized increase in PDK-1 activity or action. On the other hand, it is possible that rosiglitazone may have (a) acted on a pool of PDK-1 that specifically regulates PKC-zeta /lambda , or (b) up-regulated or down-regulated a factor(s) that selectively modulates PKC-zeta /lambda loop phosphorylation, in conjunction with, but independently of, PDK-1. Further studies are needed to (a) identify the rosiglitazone-sensitive factor(s) that regulates or modulates PKC-zeta /lambda phosphorylation and activation basally and in response to insulin stimulation, and (b) examine the relationship of the rosiglitazone-sensitive stimulatory factor(s) to the diabetes-dependent inhibitory factor(s).

It should be noted that the marked improvement in insulin-induced PKC-zeta /lambda enzyme activation in adipocytes of GK-diabetic rats observed following rosiglitazone treatment occurred despite only modest decreases in serum glucose levels, namely from approximately 329 ± 9 (n = 15) to 284 ± 9 (n = 8) mg/dl (see also Ref. 22). It therefore seems unlikely that rosiglitazone effects on PKC-zeta /lambda in adipocytes of GK rats can be explained simply by improvement of glucotoxicity. It should also be noted that there were no significant changes in serum glucose levels in nondiabetic rats following rosiglitazone treatment for either 6 or 14 days. These findings of independence of presently observed in changes in PKC-zeta /lambda activation on serum glucose levels, however, does not negate the possibility that such improvement in PKC-zeta /lambda activation might also occur through improvement in glucotoxicity.

In contrast to apparent correlations with PKC-zeta /lambda activation, rosiglitazone-induced increases in insulin-stimulated glucose transport in adipocytes of both nondiabetic and GK-diabetic rats could not be correlated to gross (a) alterations in the levels of either GLUT1 or GLUT4 glucose transporters, (b) changes in IRS-1-dependent PI 3-kinase activation, or (c) changes in the phosphorylation/activation of PKB. On the other hand, there may be specific pools of these factors that are not reflected in the gross overall assays. In any event, the present findings are compatible with the possibility that increases in insulin-stimulated glucose transport following rosiglitazone treatment in adipocytes of nondiabetic and GK-diabetic rats may have been at least partly due to increases in the phosphorylation and enzymatic activation of PKC-zeta /lambda . Obviously, further studies are needed to test this hypothesis.

In summary, insulin-stimulated glucose transport, IRS-1-dependent PI 3-kinase activation, and phosphorylation/activation of PKC-zeta /lambda were found to be defective in adipocytes of type II diabetic GK rats. Of particular interest, these defects in insulin-stimulated glucose transport and PKC-zeta /lambda phosphorylation/activation were fully or more than fully reversed by rosiglitazone treatment, despite the fact that rosiglitazone had little or no significant effect on the activation of IRS-1-dependent PI 3-kinase or PKB. Similarly, in adipocytes of nondiabetic rats, rosiglitazone increased (a) insulin-stimulated glucose transport, (b) insulin effects on the phosphorylation of threonine 410 loop and threonine 560 autophosphorylation sites in PKC-zeta , and enzymatic activation of PKC-zeta /lambda , but was without effect on PI 3-kinase or PKB activation. Our findings are compatible with the possibility that increases in insulin-induced PKC-zeta /lambda phosphorylation and activation contributed importantly to increases in glucose transport observed in isolated adipocytes following rosiglitazone treatment of GK-diabetic and nondiabetic rats. Further studies are needed (a) to see if rosiglitazone and other TZDs alter PKC-zeta /lambda activation in other animal and human states of type II diabetes mellitus, obesity, and other forms of clinical insulin resistance, and (b) to more fully define the mechanism that is responsible for increased phosphorylation and activation of PKC-zeta /lambda following TZD treatment.

    ACKNOWLEDGEMENT

We thank Sara M. Busquets for invaluable secretarial assistance.

    FOOTNOTES

* This work was supported by funds from the Department of Veterans Affairs Merit Review Program and National Institutes of Health Research Grant 2R01DK38079-09A1.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Research Service (VAR 151), J. A. Haley Veterans Hospital, 13000 Bruce B. Downs Blvd., Tampa, FL 33612. Tel.: 813-972-7662; Fax: 813-972-7623; E-mail: rfarese@com1.med.usf.edu.

Published, JBC Papers in Press, April 3, 2000, DOI 10.1074/jbc.M000287200

2 M. L. Standaert, Y. Kanoh, G. Bandyopadhyay, M. P. Sajan, and R. V. Farese, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: TZD, thiazolidinedione; PI, phosphatidylinositol; PAGE, polyacrylamide gel electrophoresis; PKC, protein kinase C; PKB, protein kinase B; GK, Goto-Kakizaki; PMSF, phenylmethylsulfonyl fluoride; KRP, Krebs-Ringer phosphate; PIP3, phosphatidylinositol-3,4,5-(PO4))3; PDK, 3-phosphoinositide-dependent protein kinase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Saltiel, A. R., and Olefsky, J. M. (1996) Diabetes 45, 1661-1669
2. Shulman, G. I. (1999) Am. J. Cardiol. 84, 3J-10J
3. Shimaya, A., Noshiro, O., Hirayama, R., Yoneta, T., Niigata, K., and Shikama, H. (1997) Eur. J. Endocrinol. 137, 693-700
4. Szalkowski, D., White-Carrington, S., Berger, J., and Zhang, B. (1995) Endocrinology 136, 1474-1481
5. Tafuri, S. R. (1996) Endocrinology 137, 4706-4712
6. Weinstein, S. P., Holand, A., O'Boyle, E., and Haber, R. S. (1993) Metabolism 42, 1365-1369
7. Shepherd, P. R., Withers, D. J., and Siddle, K. (1998) Biochem. J. 333, 471-490
8. Peraldi, P., Xu, M., and Spiegelman, B. M. (1997) J. Clin. Invest. 100, 1863-1869
9. Sizer, K. M., Smith, C. L., Jacob, C. S., Swanson, M. L., and Bleasdale, J. E. (1994) Mol. Cell. Endocrinol. 103, 1-12
10. Bandyopadhyay, G., Standaert, M. L., Zhao, L, Yu, B., Avignon, A, Galloway, L, Karnam, P., Moscat, J., and Farese, R. V. (1997) J. Biol. Chem. 272, 2551-2558
11. Bandyopadhyay, G., Standaert, J. L., Galloway, L., Moscat, J., and Farese, R. V. (1997) Endocrinology 138, 4721-4731
12. Standaert, M. L., Galloway, L., Karnam, P., Bandyopadhyay, G., Moscat, J., and Farese, R. V. (1997) J. Biol. Chem. 272, 30075-30082
13. Bandyopadhyay, G., Standaert, M. L., Kikkawa, U., Ono, Y., Moscat, J., and Farese, R. V. (1999) Biochem J 337, 461-470
14. Kotani, K., Ogawa, W., Matsumoto, M., Kitamura, M., Sakaue, H., Hino, Y., Miyake, K., Sano, W., Akimoto, K., Ohno, S., and Kasuga, M. (1998) Mol. Cell. Biol. 18, 6971-6982
15. Kohn, A. D., Summers, S. A., Birnbaum, M. J., and Roth, R. A. (1996) J. Biol. Chem. 271, 31372-31378
16. Tanti, J., Grillo, S., Gremeaux, T., Coffer, P. J., Van Obberghen, E., and Le Marchand-Brustel, Y. (1997) Endocrinology 138, 2005-2010
17. Wang, Q., Somwar, R., Bilan, P. J., Liu, Z., Jin, J., Woodgett, J. R., and Klip, A. (1999) Mol. Cell. Biol. 19, 4008-4018
18. Hill, M. M., Clark, S. F., Tucker, D. F., Birnbaum, M. J., James, D. E., and Macaulay, L. (1999) Mol. Cell. Biol. 19, 7771-7781
19. Abdel-Halim, S. M., Ostenson, C., Andersson, A., Jansson, L., and Efendic, S. (1995) Diabetes 44, 1280-1284
20. Bisbis, S., Bailbe, D., Tormo, M., Picarel-Blanchot, F., Derouet, M., Simon, J., and Portha, B. (1993) Am. J. Physiol. 265, E807-E813
21. Farese, R. V., Standaert, M. L., Yamada, K., Huang, L. C., Zhang, C., Cooper, D. R., Wang, Z., Yang, Y., Suzuki, S., Toyota, T., and Larner, J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11040-11044
22. O'Rourke, C. M., Davis, J., Saltiel, A. R., and Cornicelli, J. A. (1997) Metabolism 46, 192-198
23. Begum, N., and Ragolia, L. (1998) Metabolism 47, 54-62
24. Krook, A., Kawano, Y., Song, X. M., Efendic, S., Roth, R. A., Wallberg- Henriksson, H., and Zierath, J. R. (1997) Diabetes 46, 2110-2114
25. Song, Z. M., Kawano, Y., Krook, A., Ryder, J. W., Efendic, S., Roth, R. A., Wallberg-Henriksson, H., and Zierath, J. R. (1999) Diabetes 48, 664-670
26. Young, P. W., Cawthorne, M. A., Coyle, P. J., Holder, J. C., Holman, G. D., Kozka, I. J., Kirkham, D. M., Lister, C. A., and Smith, S. A. (1995) Diabetes 44, 1087-1092
27. Pearson, S. L., Cawthorne, M. A., Clapham, J. C., Dunmore, S. J., Holmes, S. D., Moore, G. B., Smith, S. A., and Tadayyon, M. (1996) Biochem. Biophys. Res. Commun. 229, 752-757
28. Standaert, M. L., Bandyopadhyay, G., Perez, L., Price, D., Galloway, L., Poklepovic, A., Sajan, M. P., Cenni, V., Sirri, A., Moscat, J., Toker, A., and Farese, R. V. (1999) J. Biol. Chem. 274, 25308-25316
29. Standaert, M. L., Bandyopadhyay, G., Sajan, M. P., Cong, L., Quon, M. J., and Farese, R. V. (1999) J. Biol. Chem. 274, 14074-14078
30. Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., and Parker, P. J. (1998) Science 281, 2042-2045
31. Chou, M. M., Hou, W., Johnson, J., Graham, L. K., Lee, M. H., Chen, C., Newton, A. C., Schaffhausen, B. S., and Toker, A. (1998) Curr. Biol. 8, 1069-1077
32. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., and Cohen, P. (1997) Curr. Biol. 7, 261-269
33. Stokoe, D, Stephens, L. R., Copeland, T, Gaffney, P. R. J., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F., and Hawkins, P. T. (1997) Science 277, 567-570

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
R. V. Farese, M. P. Sajan, and M. L. Standaert
Insulin-Sensitive Protein Kinases (Atypical Protein Kinase C and Protein Kinase B/Akt): Actions and Defects in Obesity and Type II Diabetes
Experimental Biology and Medicine, October 1, 2005; 230(9): 593 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. P. Sajan, M. L. Standaert, A. Miura, C. R. Kahn, and R. V. Farese
Tissue-Specific Differences in Activation of Atypical Protein Kinase C and Protein Kinase B in Muscle, Liver, and Adipocytes of Insulin Receptor Substrate-1 Knockout Mice
Mol. Endocrinol., October 1, 2004; 18(10): 2513 - 2521.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. P. Sajan, M. L. Standaert, A. Miura, G. Bandyopadhyay, P. Vollenweider, D. M. Franklin, R. Lea-Currie, and R. V. Farese
Impaired Activation of Protein Kinase C-{zeta} by Insulin and Phosphatidylinositol-3,4,5-(PO4)3 in Cultured Preadipocyte-Derived Adipocytes and Myotubes of Obese Subjects
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3994 - 3998.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. L. Standaert, M. P. Sajan, A. Miura, Y. Kanoh, H. C. Chen, R. V. Farese Jr., and R. V. Farese
Insulin-induced Activation of Atypical Protein Kinase C, but Not Protein Kinase B, Is Maintained in Diabetic (ob/ob and Goto-Kakazaki) Liver: CONTRASTING INSULIN SIGNALING PATTERNS IN LIVER VERSUS MUSCLE DEFINE PHENOTYPES OF TYPE 2 DIABETIC AND HIGH FAT-INDUCED INSULIN-RESISTANT STATES
J. Biol. Chem., June 11, 2004; 279(24): 24929 - 24934.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
E. Verrier, L. Wang, C. Wadham, N. Albanese, C. Hahn, J. R. Gamble, V. K. K. Chatterjee, M. A. Vadas, and P. Xia
PPAR{gamma} Agonists Ameliorate Endothelial Cell Activation via Inhibition of Diacylglycerol-Protein Kinase C Signaling Pathway: Role of Diacylglycerol Kinase
Circ. Res.,